BIIB · Q4 2025 Earnings
CautiousBiogen
Reported January 14, 2026
30-second summary
FY2025 non-GAAP EPS of $15.28 beat the $14.50–$15.00 guide; FY2026 initial guide of $15.25–$16.25 implies ~3% YoY growth at the midpoint despite total revenue declining mid-single digits and MS products (ex-Vumerity) declining mid-teens — the strongest explicit acknowledgement yet that MS erosion has moved from "more resilient than expected" (Q2 FY2025) to a structural mid-teen step-down. The EPS guide implies meaningful operating leverage: gross margin held flat, core OPEX flat, contract manufacturing repositioned to ~$600M annualized, and Q1 FY2026 expense running ~10% higher YoY (implying H2 spend cuts not yet detailed). Management's tone on pipeline (10 Phase 3 programs, iClick subcutaneous, litifilimab) is the most forward-leaning in over a year; the operating model is now optimization-led, not growth-led.
Guidance
EPS raised for FY2026 (+$0.75–$1.25 to $15.25–$16.25) despite guiding total revenue to decline mid-single digits and MS products to decline mid-teens; gross margin and core OPEX expected flat, signaling operational leverage and cost discipline offset commodity pressure.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Total revenue growth | FY 2026 | decline by a mid-single-digit percentage | — |
| MS products revenue (excl. Vumerity) growth | FY 2026 | decline by a mid-teen percentage | — |
| Contract manufacturing revenue | FY 2026 | roughly $300 million in each half | — |
| Gross margin | FY 2026 | roughly consistent with 2025 | — |
| Core OPEX | FY 2026 | roughly consistent with 2025 | — |
| 2026 expense vs Q1 2025 | Q1 FY2026 | roughly 10% higher | +10% YoY |
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| EPS (non-GAAP) | FY 2026 | $14.50–$15.00 | $15.25–$16.25 | +$0.75–$1.25 at midpoint | Raised |
Management tone
Q4 FY2024 MS-cliff defense → Q1 FY2025 launches gaining → Q2 FY2025 launches lead, MS resilient → Q3 FY2025 launches at $1.2B TTM, pipeline as conviction → Q4 FY2025 managed-decline operating model with pipeline transformation as the multi-year thesis
Across five quarters Biogen has migrated from defending an MS cliff to embracing a controlled revenue decline as the path to EPS growth. The Q4 FY2025 framing — total revenue down mid-single digits, MS down mid-teens, EPS guided to $15.25–$16.25 — is the most explicit articulation yet that the operating model is optimization, not growth. The anchor: "Total revenue is expected to decline by a mid-single-digit percentage for 2026 compared to 2025." That language replaces the prior "approximately flat to +1%" FY2025 guide, and it is the first time management has committed in print to a declining top line. The signal: management has decided the defensible thesis is operational leverage plus pipeline option value, not revenue continuity.
Leqembi commentary has moved across four quarters from "build infrastructure" → "infrastructure maturing" → "market-leading and market-creating" → "iClick changes the modality entirely." The anchor: "The game changer could be really the iClick for induction... Once you move to a subcutaneous injection, now we're not talking about infusions at all anymore." The shift removes the infusion-burden bottleneck that constrained neurologist throughput; if iClick approves (PDUFA May 24), the addressable practice base expands materially. The risk is reimbursement — full coverage delayed to 1-1-27.
The pipeline narrative has compounded across three quarters from "deliberate expansion" (Q3 FY2025) to "deliberate, balanced, distinct from prior Biogen." Management was unusually explicit: "This is different than the Biogen approach in the past. It is also balanced alongside our early-stage pre-POC pipeline with the high-risk, high-reward assets." Naming the strategy as a break from prior management posture is a strong claim. It also raises the cost of a Phase 3 miss — litifilimab SLE end-FY2026 and BIIB080 Phase 2 are the two readouts that will validate or undermine the framing.
A new candid note appeared on early-stage depth: "I would say today we feel pretty good about where our late-stage pipeline is, but we do need to build up our earlier-stage pipeline." Management acknowledging a depth gap is unusual for Biogen — and it is the one defensive tonal note in an otherwise expansive call. It also sets up continued BD spend as a structural feature, not a one-time charge.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Phil Nadeau · TD Cowan
When will Biogen's top line return to growth and when could growth products overtake legacy franchise declines? What role could business development play?
Growth products already outstripped EMS declines in the past year. Full-year Tecfidera generic erosion and Tysabri biosimilar will create headwinds in 2025. Return to growth requires Phase III positive results (lidophilumab in SLE/CLE by end-2025, AMR by 2028 potential launches) and/or strategic acquisitions in the $5-6B range, though finding value-accretive deals remains challenging.
Brian Scorny · Baird
How should we think about the commercial opportunity for BID-80 and what clinical data is needed to see next level of success versus Lecanemab given that intrathecal is harder than IV administration?
Tau is considered important target by neurology experts and tau levels correlate with Alzheimer's severity. Biogen can reduce tau but duration needed to impact cognition is unclear. Key questions: side effect profile (belief ARIA won't occur but needs confirmation), whether intracellular tau reduction matters more than extracellular, potential combination approaches, and sequence of tau vs amyloid treatment. Phase III would take several years post-Phase II readout.
Salveen Richter · Goldman Sachs
Given mixed Phase II lupus data and disease complexity, what supports high conviction in litophilumab Phase III outcomes?
High conviction based on: (1) BDCA2 pathway targeting exclusively PDC cells which regulate type 1 interferon signature (mechanism published in NEJM); (2) LILAC Phase II data showed proof-of-concept in both systemic and cutaneous lupus independently; (3) Primary endpoint (SRI-4) requires ≥4-point reduction with no worsening, capturing disease activity; (4) Trial design targets appropriate patient populations for mechanism. Phase III readouts SLE end-2025, CLE mid-2026.
Michael Yee · UBS
How important are BID-80 Phase II subgroup analyses (high tau vs low tau) and tau PET substudy to interpreting results?
Very important. Study designed to test scientific hypothesis through: tau PET imaging, fluid biomarkers, trends in clinical data with triangulation approach. Study includes tau substudy, three dose levels tested, two dosing regimens in randomized controlled trial format. All components described as very informative for assessing mechanisms.
Umar Rafat · Evercore
How important is hitting EGFR endpoint for pelzardimab beyond primary endpoint in AMR? Why limit development to kidney transplant vs other organ transplants?
EGFR endpoint very important; primary endpoint is focus but all secondary endpoints will be examined and totality of data will matter. Phase II showed compelling >80% effect magnitude. Regarding other transplants: company evaluating CD38 autoantibody impact in other transplant types internally. Also initiating sister indication trial on microvascular inflammation for kidney AMR. Monitoring physician experimentation with CD38 in heart transplant but not sponsoring.
Answers to last quarter's watch list
What to watch into next quarter
Q1 FY2026 OPEX print and H2 cost glide path. Management guided Q1 FY2026 expense ~10% higher YoY against flat full-year core OPEX — implying H2 FY2026 reductions that have not been detailed. Watch the Q1 print and any forward color on H2 cost actions.
MS franchise quarterly cadence within the mid-teen decline. Mid-teen FY decline implies an acceleration vs prior trajectory; watch whether the decline is front-loaded (Tysabri biosimilar EU, Tecfidera Europe) or sustained at that rate through FY2026.
Litifilimab CLE Phase 3 readout mid-FY2026. First of the two lupus readouts; a positive CLE result de-risks the SLE readout at year-end and validates the BDCA2 mechanism thesis. A miss recasts the lupus franchise as SLE-dependent.
BIIB080 Phase 2 readout (mid-FY2026). Tau-substudy data plus clinical trend signal will determine whether the second-pillar Alzheimer's program advances to Phase 3 — and whether the company can credibly position beyond Leqembi.
Leqembi iClick subcutaneous induction approval (PDUFA May 24, FY2026) and reimbursement clarity. The "game changer" framing depends on regulatory approval and on closing the gap between current Part D / formulary exemption coverage and full reimbursement at 1-1-27.
Contract manufacturing revenue trajectory. ~$600M annualized for FY2026 is a meaningful step-up from the Q3 FY2025 guide; watch whether the H1/H2 split holds and whether margin contribution matches management's "disciplined cost management" framing for flat gross margin.
Spinraza high-dose US launch (PDUFA April, FY2026). Japan launch is tracking ahead of expectations with switchbacks; US approval is the meaningful contributor to rare disease growth in FY2026.
Sources
- Biogen Q4 FY2025 earnings conference call transcript (prepared remarks and Q&A, January 13, 2026) — primary source for Q4 FY2025 actuals, FY2026 guidance, and pipeline commentary.
- Biogen Form 8-K cover page filing dated January 13, 2026: https://www.sec.gov/Archives/edgar/data/875045/000087504526000003/R1.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.